AngioDynamics Port Catheter Lawsuit
(SmartPort & Navilyst)
Growing litigation against AngioDynamics and Navilyst Medical alleging SmartPort and NMI Port catheters fracture and migrate due to design defects, causing serious injuries including embolization to the heart or lungs, bloodstream infections, and requiring emergency retrieval surgery. Cases primarily involve cancer patients.
Key Takeaways
- 375 cases pending with rapid growth since MDL creation in July 2024
- 500+ FDA adverse event reports for AngioDynamics port products
- Similar to Bard PowerPort MDL-3081 with 2,400+ cases
- Cases primarily involve cancer patients requiring chemotherapy
- Allegations include catheter fractures, migration to heart/lungs, and infections
Key Facts (May 2026)
| Pending Actions | 375 cases in federal MDL (May 2026) |
| Growth Rate | 733% growth since MDL creation |
| Defendants | AngioDynamics, Inc., Navilyst Medical, Inc. |
| Presiding Judge | Hon. Jinsook Ohta (S.D. California) |
| MDL Created | July 25, 2024 |
| First Transfer | October 3, 2024 |
| FDA Adverse Events | 500+ reports in MAUDE database (2020-2025) |
| Catheter Fracture Rate | 0.1% - 1.6% per medical literature |
| Can You Still File? | Yes, lawsuits are actively being filed |
Case Growth Since MDL Creation
This newer MDL has seen steady growth since its creation in July 2024. Case count has increased 733% as cancer patients report catheter fractures and complications.
Source: JPML MDL Statistics Reports, October 2024-May 2026
Related Litigation: Bard PowerPort (MDL-3081)
This MDL involves similar allegations to the larger Bard PowerPort MDL-3081 with 2,400+ pending cases. Both involve port catheter fractures, migrations, and infections primarily affecting cancer patients.
Source: JPML MDL Statistics Report, March 2026
1 What Is This Lawsuit About?
An implantable port (also called port-a-cath or TIVAP) is a medical device surgically placed under the skin to provide long-term vascular access for chemotherapy, IV medications, and blood draws. The device consists of a port body (reservoir) placed in the chest and a catheter tube that runs into a large central vein near the heart.
Plaintiffs allege that AngioDynamics SmartPort and Navilyst NMI Port devices are defectively designed. The catheters allegedly fracture spontaneously or at connection points, allowing fragments to migrate through the bloodstream to the heart or pulmonary arteries—requiring emergency surgical retrieval.
The lawsuits also allege the devices are prone to catheter-related bloodstream infections (CRBSIs), sepsis, and thrombosis (blood clots). These complications are particularly dangerous for cancer patients who are already immunocompromised from treatment.
2 Products at Issue
The litigation involves port catheter products manufactured by AngioDynamics and its Navilyst Medical subsidiary:
AngioDynamics Products
- SmartPort+ — Implantable ports (510(k) K190559)
- SmartPort CT Series — Power-injectable port systems
- SmartPort CT Vortex — Low profile titanium ports
- BioFlo Products — Vascular access products with BioFlo technology
Navilyst Medical Products
- NMI Port — Implantable port system (510(k) K122767)
- NMI Port II — Second generation port (510(k) K153228)
- NMI Dual Port II — Dual lumen port (510(k) K151239)
3 Reported Complications & Injuries
The FDA MAUDE database contains over 500 adverse event reports for AngioDynamics port products from 2020-2025. Reported complications include:
Catheter Fracture & Migration
- Spontaneous catheter fracture inside the body
- Fragments embolize to heart or pulmonary arteries
- Incidence rate: 0.1% - 1.6% per medical literature
- Requires interventional radiology retrieval
Bloodstream Infections
- Catheter-related bloodstream infections (CRBSI)
- Sepsis (life-threatening systemic infection)
- Bacteremia requiring hospitalization
- Especially dangerous for immunocompromised patients
Blood Clots (Thrombosis)
- Deep vein thrombosis (DVT)
- Pulmonary embolism risk
- Port occlusion requiring intervention
Other Complications
- Pinch-off syndrome (catheter compression)
- Cardiac arrhythmias from fragments
- Catheter disconnection from port body
- Death (in severe cases)
4 FDA Regulatory History
FDA clears SmartPort CT MP Port Access System (K072375). Class II device cleared without clinical trials.
Multiple SmartPort and NMI Port variants cleared including CT Series, Vortex, low profile titanium, and dual port versions.
FDA recall of 8F Smart Port CT products (Catalog Numbers CT80STPD and CT80STPD-NF).
FDA recall (Z-1466-2021) of Smart Port CT products for potential compromised sterility due to Valved Introducers susceptible to failure.
FDA MAUDE database contains over 500 adverse event reports for AngioDynamics products (2020-2025), including fractures, migrations, and infections.
5 Do You Qualify for Compensation?
You may be eligible to file a claim if you meet these criteria:
Eligibility Requirements
- Had an AngioDynamics or Navilyst port implanted — Including SmartPort, SmartPort CT, NMI Port, BioFlo, or similar products
- Experienced a qualifying complication — Catheter fracture, fragment migration/embolization, bloodstream infection/sepsis, deep vein thrombosis, or required surgical removal
- Can document the device and injury — Medical records showing device implantation and subsequent complications
- Within statute of limitations — Generally 2-3 years from injury discovery, varies by state
6 Frequently Asked Questions
What is an implantable port catheter?
What are the alleged defects?
What injuries are included in the lawsuit?
Who are the defendants?
How does this compare to the Bard PowerPort MDL?
Have there been any settlements?
Can I still file a lawsuit?
Sources & References
8 official sources cited• JPML MDL Statistics Report — Pending MDL Dockets (December 2, 2025)
• FDA 510(k) Premarket Notification Database — Device clearance records (K072375, K081472, K101017, K122767, K131694, K151239, K153228, K190559)
• FDA MAUDE Database — 500+ adverse event reports for AngioDynamics products (2020-2025)
• FDA Medical Device Recalls Database — Class 2 recalls (Z-1466-2021, October 2011)
• Burbridge B et al. "Catheter fracture and embolization associated with arm implantation of the cook vital port." Can Assoc Radiol J. 2013;64(3):269-73. (PMID: 22867962)
• D'Souza PC et al. "Complications and Management of Totally Implantable Central Venous Access Ports in Cancer Patients." Sultan Qaboos Univ Med J. 2021. (PMID: 33777430)
• SEC EDGAR Database — AngioDynamics company filings (CIK: 0001275187)
• U.S. District Court, Southern District of California — MDL-3125 case docket (3:24-md-3125)
Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content.
Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.